
Rectal Cancer Rewrites the Surgery Pathway
FDA has granted accelerated approval to dostarlimab for MSI-H/dMMR stage II–III locally advanced rectal cancer. For selected responding patients, the treatment strategy can now be…
Rectal Cancer Rewrites the Surgery Pathway
Late Thrombectomy Extends Benefit and Risk
Food Safety’s 1.5 Million-Death Reckoning
Retinal Vessel Changes May Help Refine Glaucoma Risk Assessment
Heart failure has a weather problem. Health systems need to plan for it
NAD boosters are sold as anti-ageing. Whole-blood data challenge the premise
IPM Brief – Issue 45 | The pathway is becoming the product. And politics is catching up.
Explore by disease area
Alerts
See all →Signals
See all →
Retinal Vessel Changes May Help Refine Glaucoma Risk Assessment

Heart failure has a weather problem. Health systems need to plan for it

Rectal Cancer Rewrites the Surgery Pathway
FDA has granted accelerated approval to dostarlimab for MSI-H/dMMR stage II–III locally advanced rectal cancer. For selected responding patients, the treatment strategy can now be…
Playbook
See all →
IPM Brief – Issue 45 | The pathway is becoming the product. And politics is catching up.
By Denis Horgan, Secretary General of the International Alliance for Personalised Medicine
IPM Brief – Issue 44 | Show us the patient
By Denis Horgan, Secretary General of the International Alliance for Personalised Medicine
IPM Brief – Issue 43 | The Bill Comes Due – Even Without a Licence to Kill
By Denis Horgan, Secretary General of the International Alliance for Personalised Medicine
IPM Brief – Issue 42 | Mind the Fuse
By Denis Horgan, Secretary General of the International Alliance for Personalised Medicine
IPM Brief – Issue 41 | The system is the treatment
By Denis Horgan, Secretary General of the International Alliance for Personalised Medicine
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
By subscribing, you agree to receive updates from IPM Alliance. You can unsubscribe at any time. For more information, please see our Privacy Policy.































